Key clinical point: Monalizumab + cetuximab is safe, active in recurrent or metastatic SCC of the head and neck.
Major finding: Overall response rate in 40 evaluable patients was 27.5%,with 1 CR and 10 PRs at 8 weeks.
Study details: A cohort expansion of 40 patients in the single-arm, non-randomized phase 1/2 study.
Disclosures: Dr. Cohen reported receiving consulting fees and/or research funding from Cantargia, Celldex, Genocea, Innate, HEAT, Kyntherapeutics, Merck, Takeda Macrogenics, and Tmunity.
Cohen R et al. SITC 2018, Abstract 051.